|Generic name||Brentuximab vedotin|
|Brand name(s), other common name(s)||Adcetris®|
|Drug type||Antibody conjugate|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Brentuximab vedotin is FDA approved for the treatment of adult patients with:
- Previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine
- Classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation
- Classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
- Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone
- Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen
- Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30- expressing mycosis fungoides (MF) who have received prior systemic therapy .
Side effects needing medical attention
Peripheral neuropathy; infusion reactions; low white cell counts; fatigue; nausea; anemia; upper respiratory tract infection; diarrhea; fever; rash; low platelet counts; cough; vomiting.
Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, has been reported with brentuximab vedotin.
The FDA warns against use of brentuximab vedotin with the cancer drug bleomycin due to increased risk of pulmonary toxicity.